Table 3.
Patient characteristics of improvement group and non-improvement group
| Improvement ( n = 42) | Non-improvement ( n = 36) | p value | |
|---|---|---|---|
| Sex (male/female) | 24/18 | 26/10 | 0.237 |
| Age (years) | 69 (13) | 71 (34) | 0.996 |
| APACHE II score | 24 (12) | 24 (12) | 0.980 |
| SOFA score | 11 (4) | 11 (7) | 0.996 |
| MAP at baseline (mmHg) | 62 (10) | 72 (22) | 0.343 |
| Creatinine at baseline (mg/dl) | 1.28 (1.72) | 1.65 (1.85) | 1.000 |
| Lactate level at baseline (mmol/L) | 3.2 (5.9) | 4.2 (4.9) | 0.599 |
| Patients with diabetes mellitus | 13 | 11 | 1.000 |
| Patients received corticosteroid therapy | 8 | 5 | 0.762 |
| The times of PMX therapy | 1 (1) | 1 (1) | 0.281 |
| Total PMX treatment time (min) | 1598 (2972) | 1412 (2254) | 0.237 |
| Inotropic score at pre-PMX | 24.7 (21.0) | 10.3 (18.6) | 0.001 |
| Inotropic score at post-PMX | 6.8 (15.6) | 16.6 (32.8) | 0.037 |
| Vasopressor dependency index at pre-PMX (/mmHg) | 0.33 (0.44) | 0.19 (0.29) | 0.019 |
| Vasopressor dependency index at post-PMX(/mmHg) | 0.13 (0.26) | 0.14 (0.28) | 0.845 |
| PaO2/FIO2 ratio at pre-PMX | 210 (234) | 199 (206) | 0.980 |
| PaO2/FIO2 ratio at post-PMX | 254 (181) | 172 (156) | 0.041 |
| Endotoxin level before the PMX treatment (pg/mL) | 15.8 (60.5) | 6.1 (23.7) | 0.195 |
| Endotoxin level after the PMX treatment (pg/mL) | 1.4 (18.2) | 0.8 (0.7) | 0.267 |
| Suspected causative microorganisms (GNR/GPC/GPR/unknown origin) | 24/6/2/10 | 17/6/0/13 | 0.428 |
| Median survival time (days) | 72 | 131 | 0.172 |
| Ventilator-dependent time (days) | 13 (33) | 7 (42) | 0.557 |
Data are presented as number of cases or median (IQR). IQR interquartile range, MAP mean arterial pressure, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, PMX polymyxin B-immobilized fiber column hemoperfusion, GNR Gram-negative rod, GPC Gram-positive cocci, GPR Gram-positive rods.